Home Cart Sign in  
Chemical Structure| 775351-61-6 Chemical Structure| 775351-61-6

Structure of Imeglimin HCl
CAS No.: 775351-61-6

Chemical Structure| 775351-61-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Imeglimin HCl is the first in a tetrahydrotriazine-containing class of oral antidiabetic agents, the glimins.

Synonyms: EMD 387008 hydrochloride; Imeglimin hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Imeglimin HCl

CAS No. :775351-61-6
Formula : C6H14ClN5
M.W : 191.66
SMILES Code : [H]Cl.NC1=N[C@@H](C)N=C(N(C)C)N1
Synonyms :
EMD 387008 hydrochloride; Imeglimin hydrochloride
MDL No. :MFCD28167741
InChI Key :UXHLCYMTNMEXKZ-PGMHMLKASA-N
Pubchem ID :54763513

Safety of Imeglimin HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.22mL

1.04mL

0.52mL

26.09mL

5.22mL

2.61mL

52.18mL

10.44mL

5.22mL

References

[1]Fouqueray P, Pirags V, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013 Mar;36(3):565-8.

[2]Pirags V, Lebovitz H, et al. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012 Sep;14(9):852-8.

[3]Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021 Mar;23(3):664-673

[4]Vial G, Lamarche F, Cottet-Rousselle C, Hallakou-Bozec S, Borel AL, Fontaine E. The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells. Endocrinol Diabetes Metab. 2021 Feb 23;4(2):e00211

[5]Vuylsteke V, Chastain LM, Maggu GA, Brown C. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes. Drugs R D. 2015 Sep;15(3):227-32

[6]Perry RJ, Cardone RL, Petersen MC, Zhang D, Fouqueray P, Hallakou-Bozec S, Bolze S, Shulman GI, Petersen KF, Kibbey RG. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E461-70

[7]Detaille D, Vial G, Borel AL, Cottet-Rouselle C, Hallakou-Bozec S, Bolze S, Fouqueray P, Fontaine E. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016 Jan 18;2:15072

 

Historical Records

Categories